PE20090239A1 - ANTAGONISTAS CRIg - Google Patents
ANTAGONISTAS CRIgInfo
- Publication number
- PE20090239A1 PE20090239A1 PE2008000774A PE2008000774A PE20090239A1 PE 20090239 A1 PE20090239 A1 PE 20090239A1 PE 2008000774 A PE2008000774 A PE 2008000774A PE 2008000774 A PE2008000774 A PE 2008000774A PE 20090239 A1 PE20090239 A1 PE 20090239A1
- Authority
- PE
- Peru
- Prior art keywords
- crig
- scfv
- fab
- clearing
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL HUMANIZADO O UN FRAGMENTO DEL MISMO SELECCIONADO DE Fab, Fab', F(ab')2, scFv, (scFv)2 O dAb, QUE ES UN ANTAGONISTA DEL RECEPTOR ASOCIADO AL MACROFAGO CRIg QUE BLOQUEA EL ENLACE DE UN POLIPEPTIDO CRIg INHIBIENDO LA ENTRADA CELULAR DEPENDIENTE DEL COMPLEMENTO MEDIADA POR CRIg DE UN PATOGENO INTRACELULAR TAL COMO UN VIRUS DE ARN O ADN, PARASITO, BACTERIA, HONGO O PRION, O DEPURANDO UN PATOGENO INTRACELULAR DE LA CIRCULACION. DICHO ANTICUERPO ES ANTI-CRIg MONOCLONAL SELECCIONADO DE 14G8, 3D10 O 2H1. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO ANTI-CRIg SIENDO UTIL ADEMAS EN LA PREVENCION DE LA DEPURACION NO DESEADA DE ERITROCITOS Y PLAQUETAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91534007P | 2007-05-01 | 2007-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090239A1 true PE20090239A1 (es) | 2009-03-19 |
Family
ID=39645433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000774A PE20090239A1 (es) | 2007-05-01 | 2008-04-30 | ANTAGONISTAS CRIg |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090162356A1 (es) |
EP (1) | EP2152749A1 (es) |
JP (1) | JP2010526076A (es) |
KR (1) | KR20100018523A (es) |
CN (1) | CN101675078A (es) |
AR (1) | AR066375A1 (es) |
AU (1) | AU2008247958A1 (es) |
BR (1) | BRPI0810926A2 (es) |
CA (1) | CA2682835A1 (es) |
CL (1) | CL2008001238A1 (es) |
IL (1) | IL201165A0 (es) |
MX (1) | MX2009011407A (es) |
PE (1) | PE20090239A1 (es) |
RU (1) | RU2009144280A (es) |
WO (1) | WO2008137338A1 (es) |
ZA (1) | ZA200906812B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
AU2009244300B2 (en) * | 2008-05-06 | 2014-04-17 | Genentech, Inc. | Affinity matured CRIg variants |
US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体***抑制剂、其制备方法及应用 |
CN105924515B (zh) * | 2016-04-25 | 2019-06-14 | 中国人民解放军第三军医大学 | 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN110944666A (zh) * | 2017-06-26 | 2020-03-31 | 博奥泰克尼公司 | 杂交瘤克隆、vsig-4的单克隆抗体,以及制备和使用的方法 |
EP3873929A4 (en) * | 2018-09-28 | 2022-11-23 | Eutilex Co., Ltd. | ANTI-HUMAN VSIG4 ANTIBODIES AND USES THEREOF |
US20220233756A1 (en) * | 2019-05-17 | 2022-07-28 | George A. Herzlinger | Methods and systems for treating microbial disease |
KR20220088847A (ko) * | 2019-09-04 | 2022-06-28 | 주식회사 와이바이오로직스 | 항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도 |
EP4301786A1 (en) | 2021-03-03 | 2024-01-10 | Pierre Fabre Medicament | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
-
2008
- 2008-04-25 AU AU2008247958A patent/AU2008247958A1/en not_active Abandoned
- 2008-04-25 MX MX2009011407A patent/MX2009011407A/es active IP Right Grant
- 2008-04-25 CN CN200880014866A patent/CN101675078A/zh active Pending
- 2008-04-25 EP EP08769166A patent/EP2152749A1/en not_active Withdrawn
- 2008-04-25 WO PCT/US2008/061513 patent/WO2008137338A1/en active Application Filing
- 2008-04-25 KR KR1020097024920A patent/KR20100018523A/ko not_active Application Discontinuation
- 2008-04-25 JP JP2010506507A patent/JP2010526076A/ja active Pending
- 2008-04-25 RU RU2009144280/10A patent/RU2009144280A/ru not_active Application Discontinuation
- 2008-04-25 US US12/150,220 patent/US20090162356A1/en not_active Abandoned
- 2008-04-25 CA CA002682835A patent/CA2682835A1/en not_active Abandoned
- 2008-04-25 BR BRPI0810926-5A2A patent/BRPI0810926A2/pt not_active IP Right Cessation
- 2008-04-30 AR ARP080101847A patent/AR066375A1/es not_active Application Discontinuation
- 2008-04-30 PE PE2008000774A patent/PE20090239A1/es not_active Application Discontinuation
- 2008-04-30 CL CL2008001238A patent/CL2008001238A1/es unknown
-
2009
- 2009-09-24 IL IL201165A patent/IL201165A0/en unknown
- 2009-09-30 ZA ZA2009/06812A patent/ZA200906812B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR066375A1 (es) | 2009-08-12 |
MX2009011407A (es) | 2009-11-05 |
EP2152749A1 (en) | 2010-02-17 |
CL2008001238A1 (es) | 2008-11-07 |
RU2009144280A (ru) | 2011-06-10 |
IL201165A0 (en) | 2010-05-17 |
KR20100018523A (ko) | 2010-02-17 |
CN101675078A (zh) | 2010-03-17 |
JP2010526076A (ja) | 2010-07-29 |
WO2008137338A1 (en) | 2008-11-13 |
US20090162356A1 (en) | 2009-06-25 |
BRPI0810926A2 (pt) | 2014-11-04 |
ZA200906812B (en) | 2010-12-29 |
AU2008247958A1 (en) | 2008-11-13 |
CA2682835A1 (en) | 2008-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090239A1 (es) | ANTAGONISTAS CRIg | |
PE20091029A1 (es) | Anticuerpos anti-alfa 5 beta 1 | |
PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
MY159517A (en) | A monoclonal antibody and a method thereof | |
UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
RS53291B (en) | BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES | |
PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
WO2016154047A3 (en) | Monoclonal antigen-binding proteins to intracellular oncogene products | |
MX2013012201A (es) | Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
GEP20156214B (en) | Monoclonal antibodies | |
RS54624B1 (en) | MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3 | |
MA34520B1 (fr) | Anticorps se liant à la myostatine, compositions et procédés | |
RS54056B1 (en) | ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
EP2535351A3 (en) | Dual specificity antibody fusions | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |